

Gilead Sciences Latvia EFPIA Report 2017

Article 2 - Section 2.03

Full Name	HCPs: City of Principal Practice HCOs: city where registered	Country of Principal Practice	Principal Practice Address	Unique country identifier OPTIONAL	Donations and Grants to HCOs	Contribution to costs of Events (Art 3.01.1.b & 3.01.2.a)			Fee for service and consultancy (Art 3.01.1 c & 3.01.2.c)		Information on financial and non-financial support to research defined in Chapter 3.04. and Schedule 1 (3.04.pants)	TOTAL OPTIONAL	
						(Art 1.01)	(Art 3)	(Schedule 1)	(Art 3)	(Art 3)			(Art 3.01.1.a)
INDIVIDUAL DISCLOSURE	INDIVIDUAL NAMED DISCLOSURE-one Line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up:itemization should be available for the Individual Recipient or public authorities' consultation only, as appropriate)												
	OTHER, NOT INCLUDED ABOVE-where information cannot be disclosed on an individual basis for legal reasons												
	Aggregate amount attributable to transfers of value to such Recipients - Art 3.02							800,00 €	1.417,73 €	576,00 €	374,12 €		3.167,85
	Number of Recipients in aggregate disclosure - Art 3.02							1	1	1	1		
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art 3.02							100,00	100,00	100,00	100,00		

	Full Name
--	---

R & D	AGGREGATE DISCLOSURE		
	Transfers of Value re Research & Development as defined - Article 3.04 and schedule 1	1.376,00 €	3.167,85 €